Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
94 stopped studies mapped to Throat Carcinoma and descendants · 91% state a reason
Over the 94 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05290194 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of… | Phase 2 | withdrawn | Mar 22, 2022 | Fifth Affiliated Hospital, Sun Yat-Sen University | The study was terminated because the protocol was upgraded after being considered insufficiently… | Other (stated, no rule matched) |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug… | Phase 2 | suspended | Jun 15, 2023 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Phase 2 / Phase 3 | suspended | Mar 14, 2013 | National Cancer Institute (NCI) | Other - Assessing accrual feasibility | Enrollment / accrual |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation… | Phase 2 / Phase 3 | suspended | Sep 20, 2021 | NRG Oncology | End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis | Other (stated, no rule matched) |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive… | Phase 2 | terminated | Jan 10, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)… | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment | Enrollment / accrual |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients…(OPPIDOM) | N/A | terminated | Mar 17, 2021 | Institut de cancérologie Strasbourg Europe | organisationnal reason | Other (stated, no rule matched) |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell…(HN1901) | Phase 2 | terminated | Jun 24, 2020 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | unmet primary endpoint | Other (stated, no rule matched) |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual… | Phase 3 | terminated | Jul 7, 2020 | National Cancer Institute (NCI) | External information | Other (stated, no rule matched) |
| NCT02363400 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | Phase 3 | terminated | Feb 16, 2015 | National Health Research Institutes, Taiwan | Recruiting progress behind expectation | Enrollment / accrual |
| NCT06362421 | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer | — | withdrawn | Apr 12, 2024 | Wake Forest University Health Sciences | PI not moving forward with study at our institution | Other (stated, no rule matched) |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | Phase 2 | withdrawn | Nov 8, 2022 | Case Comprehensive Cancer Center | PI left | Investigator |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | Early Phase 1 | terminated | Jul 11, 2016 | Wake Forest University Health Sciences | Study closed prior to meeting enrollment goal and funding issues | Enrollment / accrual |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing… | Phase 1 | terminated | Oct 19, 2020 | Hyunseok Kang, MD | Slow Accrual | Enrollment / accrual |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and… | Phase 2 | terminated | Nov 14, 2019 | University of Utah | Insufficient funding | Funding |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr… | Phase 1 / Phase 2 | terminated | Dec 7, 2018 | Atara Biotherapeutics | Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data Review… | Safety / toxicity |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA… | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Novartis has chosen to withdraw support for this trial | Other (stated, no rule matched) |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for…(NPC) | N/A | terminated | Jan 3, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced… | N/A | withdrawn | Oct 28, 2019 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for… | N/A | terminated | Feb 8, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122…(PANTHEoN) | Phase 1 | withdrawn | May 19, 2021 | Jennifer Choe | Funding | Funding |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before… | Phase 1 / Phase 2 | terminated | Aug 7, 2018 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive… | Phase 1 / Phase 2 | terminated | Sep 24, 2018 | Cullinan Therapeutics Inc. | Lack of efficacy | Efficacy / futility |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | terminated | Mar 3, 2016 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT03544099 | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr… | Phase 2 | terminated | Jun 1, 2018 | National Health Research Institutes, Taiwan | Difficult to recruit Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA | Enrollment / accrual |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With… | Phase 1 | withdrawn | Apr 11, 2011 | Fox Chase Cancer Center | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. | Enrollment / accrual |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With… | Early Phase 1 | terminated | Oct 21, 2015 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer… | Phase 2 | terminated | Sep 28, 2016 | National Cancer Institute (NCI) | Low accrual combined with expiration of study drug | Enrollment / accrual |
| NCT05512767 | A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage… | N/A | withdrawn | Aug 23, 2022 | Mayo Clinic | PI retired and study not moving forward | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | N/A | terminated | Jul 3, 2013 | Paul W. Read, MD | Study had very specific inclusion/exclusion criteria and difficult to recruit | Enrollment / accrual |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | withdrawn | Apr 5, 2021 | University of Miami | Investigator Decision | Investigator |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Phase 2 | withdrawn | Jun 28, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor withdrew funding | Funding |
| NCT02289807 | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated… | N/A | withdrawn | Nov 13, 2014 | Sun Yat-sen University | not stated | Not stated |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2… | Phase 2 | withdrawn | Jan 4, 2018 | The University of Hong Kong | Sponsor withdrew funding for Nivolumab | Funding |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck… | N/A | terminated | Jun 30, 2014 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic… | Phase 2 | withdrawn | Jan 18, 2020 | Alain Algazi | Feasibility | Other (stated, no rule matched) |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | Phase 1 | terminated | Jun 8, 2015 | University of Texas Southwestern Medical Center | unexpected toxicities | Safety / toxicity |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT00181220 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal… | Phase 1 | withdrawn | Sep 16, 2005 | Johns Hopkins University | PI left JHU and is not able to be reached for updates | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials